compound semaglutide lawsuit Ozempic® How the FDA's Semaglutide Ruling

Foundayo is the brand name for orforglipron, an oral GLP-1 medication approved by the FDA in April 2026 for chronic weight management

Geographic expansion remains an ongoing priority

However, it has been shown to be very effective in helping patients with overweight or obesity lose weight, and is sometimes prescribed off-label for weight loss

Here's what we'll cover Here's what we'll cover Here's what we'll cover Subcutaneous injections, which are injections administered just under the skin, can be used to deliver a wide range of medications

Turn the dose selector until your prescribed dose appears (0.25 mg, 0.5 mg, 1 mg, or 2 mg)

Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Ania M